This study is for patients who have Stage IV metastatic colorectal cancer and their disease has progressed through standard therapy.Protocol number:
Type of cancer: Stage IV Metastatic Colorectal Cancer
Phase number: I
Summary: This is a Phase 1 study for patients with Stage IV metastatic colorectal cancer whose disease has progressed through standard chemotherapy. The patientÕs tumor must be either KRAS mutant or BRAF mutant. The study uses an oral pill that is a MEK inhibitor. The study will look at effects of ARRY (the study drug) on colorectal tumors.